14 July 2025 - Atara Biotherapeutics resubmits tabelecleucel biologics license application for treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease to the US FDA.

Atara Biotherapeutics today announced that it has resubmitted a biologics license application to the US FDA for tabelecleucel (Ebvallo) indicated as monotherapy for treatment of adult and paediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease who have received at least one prior therapy.

Read Atara Biotherapeutics press release